With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus, there have been many valuable collaborations entering the RNA-targeting field, accelerating efficacious and selective small molecules targeting RNA directly, RNA-binding proteins, and RNA/protein complexes. Hence, as the go-to meeting for the RNA-targeting small molecule community, the 7th Annual RNA-Targeted Drug Discovery & […]

With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? With assets in nephrology, ophthalmology, neurodegeneration, and inflammation all progressing through to the clinic, the immunology landscape is preparing to be […]

The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. With sessions led by Almac Discovery, AstraZeneca, Bolt Biotherapeutics, and many other industry leaders, leave this […]

Join industry leaders like Eli Lilly, Merck, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12, 2024 – Philadelphia, PA). This is your perfect moment to network with enzyme discovery, engineering, biocatalysis, and process chemistry professionals from both industry and academia. Capitalize on Enzyme Evolution through HTP Screening, Advanced Engineering & […]

Join 100+ leading PAT scientists, engineers, process development, CMC, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve, exceeding stakeholder expectations for faster time to market, and unlocking significant […]

Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies: The European market is capturing 30% of the global medical device field driven by rapid advances in innovative software, AI, and ML. But as medical […]

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. Whether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran, with two dedicated tracks […]

RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms, as well as pharma giants partnering with innovative biotech companies to […]

The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity, PKPD, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors, […]

Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. The 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss […]

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it […]

The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation. With ongoing challenges including selectivity and resistance in small molecule inhibitors, these hurdles limit the therapeutic applications and call for in-depth discussions focused on […]

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS. With AbbVie, BMS, and Lundbeck making major acquisitions in the last 12 months alone, this wave of deal-making is redemption for biotech who kept the lights on and are […]

In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market, valued at $1.5 billion in 2023, is projected to skyrocket to $22.3 billion by 2029. However, scaling up production remains a significant challenge, highlighting […]

Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. Agenda highlights include: Standardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum. It’s not just investments that are gaining traction. Recent approvals are changing […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. Yet, despite optimized analytics, critical quality control methodology and robust assay development leading to efficient approvals and commercialization, knowledge gaps persist in phase-appropriate assays, analyzing […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination approaches all take off! So, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March, to showcase all […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge in multi-billion-dollar acquisitions, commercialisation deals, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit, uniting AD, QC and regulatory experts, this summit works to design potency assays that not only conform to changing guidelines but also streamline […]

The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable, traceable, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development, to ensure safe and timely delivery to […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However, challenges persist, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access, managing global supply chains, importation, licensing, […]

With Merck's acquisition of EyeBio for $1.3 Billion, Roche's Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF, explore biosimilars, and target retinal fibrosis and more […]

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the way towards a new generation of more targeted, safer and efficacious novel conjugated drugs. The 4th Novel Conjugates Summit is the only event offering comprehensive […]

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare […]

In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery […]

As the biopharma industry evolves with rapid advancements in drug development, manufacturing, and research, EHS leaders are tasked with safeguarding employee health, maintaining a culture of safety, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic […]

Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have […]

The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response, there has […]